Total number and frequency of IgD versus CD38 B-cell subsets in patients with cGVHD 2 years after rituximab
| . | Stable/improved cGVHD (n = 11) . | Unresponsive cGVHD (n = 9) . | P . |
|---|---|---|---|
| Total no. of B-cell subsets, × 106/L | |||
| Naive (IgD+CD38Lo) | 28.28 (2.2-399.6) | 0.57 (0.1-45.4) | .002 |
| Transitional (IgD+CD38++) | 5.49 (0.7-138.5) | 0.23 (0.0-17.2) | .002 |
| Memory (IgDLoCD38Lo) | 27.02 (0.9-345.3) | 1.2 (0.76-7.7) | .005 |
| Plasmablast (IgD+CD38++) | 9.11 (0.9-31.9) | 0.36 (0.1-4.8) | .002 |
| Frequency of B-cell subsets, % | |||
| Naive (IgD+CD38Lo) | 39.8 (5.9-68.3) | 14.8 (2.2-73.5) | .13 |
| Transitional (IgD+CD38++) | 11.7 (0.5-35.9) | 6.6 (0.0-19.3) | .32 |
| Memory (IgDLoCD38Lo) | 12.9 (8.9-75.1) | 31.5 (8.4-61.3) | .08 |
| Plasmablast (IgD+CD38++) | 5.8 (2.6-18.3) | 18.7 (1.0-37.2) | .20 |
| . | Stable/improved cGVHD (n = 11) . | Unresponsive cGVHD (n = 9) . | P . |
|---|---|---|---|
| Total no. of B-cell subsets, × 106/L | |||
| Naive (IgD+CD38Lo) | 28.28 (2.2-399.6) | 0.57 (0.1-45.4) | .002 |
| Transitional (IgD+CD38++) | 5.49 (0.7-138.5) | 0.23 (0.0-17.2) | .002 |
| Memory (IgDLoCD38Lo) | 27.02 (0.9-345.3) | 1.2 (0.76-7.7) | .005 |
| Plasmablast (IgD+CD38++) | 9.11 (0.9-31.9) | 0.36 (0.1-4.8) | .002 |
| Frequency of B-cell subsets, % | |||
| Naive (IgD+CD38Lo) | 39.8 (5.9-68.3) | 14.8 (2.2-73.5) | .13 |
| Transitional (IgD+CD38++) | 11.7 (0.5-35.9) | 6.6 (0.0-19.3) | .32 |
| Memory (IgDLoCD38Lo) | 12.9 (8.9-75.1) | 31.5 (8.4-61.3) | .08 |
| Plasmablast (IgD+CD38++) | 5.8 (2.6-18.3) | 18.7 (1.0-37.2) | .20 |